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Background: In assisted reproductive treatments, embryos remaining after fresh embryo transfer are usually
selected for cryopreservation based on traditional morphology assessment. Our previous report has demonstrated
that array comparative genomic hybridization (aCGH) screening for IVF patients with good prognosis significantly
improves clinical and ongoing pregnancy rates in fresh embryo transfer cycles. The current study further
investigates the efficiency of applying aCGH in the selection of euploid embryos for cryopreservation as related to
pregnancy and implantation outcomes in subsequent frozen embryo transfer (FET) cycles.
Methods: First-time IVF patients with good prognosis undergoing fresh single embryo transfer and having at least
one remaining blastocyst for cryopreservation were prospectively randomized into two groups: 1) Group A patients
had embryos assessed by morphology first and then by aCGH screening of trophectoderm cells and 2) Group B
patients had embryos evaluated by morphology alone. All patients had at least one blastocyst available for
cryopreservation after fresh embryo transfer. There were 15 patients in Group A and 23 patients in Group B who
failed to conceive after fresh embryo transfer and completed the FET cycles. Blastocyst survival and implantation
rates were compared between the two groups.
Results: There were no significant differences in blastocyst survival rates between Group A and Group B (90.9% vs.
91.3%, respectively; p >0.05). However, a significantly higher implantation rate was observed in the morphology
assessment plus aCGH screening group compared to the morphology assessment alone group (65.0% vs. 33.3%,
respectively; p = 0.038). There was no miscarriage observed in Group A while a 16.7% miscarriage rate was recorded
in Group B (0% vs. 16.7%, respectively; p >0.05).
Conclusions: While aCGH screening has been recently applied to select euploid blastocysts for fresh transfer in
young, low-risk IVF patients, this is the first prospective study on the impact of aCGH specifically on blastocyst
survival and implantation outcomes in the subsequent FET cycles of IVF patients with good prognosis. The present
study demonstrates that aCGH screening of blastocysts prior to cryopreservation significantly improves implantation
rates and may reduce the risk of miscarriage in subsequent FET cycles. Further randomized clinical studies with a
larger sample size are needed to validate these preliminary findings.
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In the procedure of in vitro fertilization, selection of blas-
tocysts for transfer or cryopreservation is routinely
conducted on the basis of morphology assessment [1,2].
Since morphological evaluation alone cannot exclude the
potential for chromosomal errors in the selected embryos,
the transfer or cryopreservation of morphologically “nor-
mal-looking” embryos without aneuploidy screening car-
ries unavoidable risk [3-6]. Numerous studies on human
oocytes and embryos derived from IVF cycles have shown
that aneuploidy is the most common abnormality [7-13],
and the high percentage of chromosomal abnormalities
contributes substantially to poor reproductive outcomes
and miscarriages observed in fertility treatments [3,5,14].
As other investigators have reported [15-19], screening
embryos by fluorescence in situ hybridization (FISH) was
a preliminary solution to this problem, but the approach
was very limited since it could only screen 5 to 12 chro-
mosomes in each embryo. Conventional comparative gen-
omic hybridization (CGH) was then introduced to screen
all 23 pairs of human chromosomes with some success
[20-23]. More recently, array comparative genomic
hybridization (aCGH) [5,6,24-30], single nucleotide poly-
morphism (SNP) array [31-35] and PCR-based compre-
hensive chromosomal screening (CCS) [36] have been
applied to screen embryos before transfer in order to
improve the efficiency of IVF treatments. These tech-
niques enable fresh or frozen embryo transfer so that
only euploid embryos are selected for transfer or freez-
ing, thus improving pregnancy and implantation out-
comes [5,6,26-28,30,34,36]. However, since experience of
using the molecular cytogenetic tests in reproductive
medicine is still limited, there is an urgent need to evalu-
ate embryo selection techniques before such technology
enters the clinical mainstream [3,6,14,34,35,37,38]. While
the optimal genome-wide molecular test for determining
the chromosomal status of human embryos remains un-
solved [35], there has been very limited information
concerning how such technology might affect embryo
cryopreservation as related to pregnancy and implantation
outcomes in subsequent FET cycles of young, low-risk
IVF patients [39]. Therefore, this prospective study is
aimed at investigating the impact of aCGH screening on
pregnancy and implantation outcomes in subsequent FET
cycles of IVF patients with good prognosis.
Methods
Patient enrollment and inclusion criteria
First-time IVF patients at our clinics in USA and PR China
were recruited in this Institutional Review Board Services
(IRB Service) approved prospective study. A written in-
formed consent was obtained from all study participants
and all patients received counseling about aCGH screening
and cryopreservation. The inclusion criteria include: 1)first time IVF treatment, 2) under 35 year old, 3) no his-
tory of miscarriage, 4) presence of both ovaries, 5)
normal karyotype, 6) normal endometrial contour, 7)
day 2 serum FSH <10 IU/l and estradiol <60 pg/ml. The
eligible patients were randomized into two groups: Group
A patients (n = 55) had their embryos assessed by morph-
ology criteria plus aCGH testing and Group B patients (n
= 48) had their embryos evaluated by morphology assess-
ment alone. No patients in this study had embryos
assigned to both cohorts. All patients had at least one
blastocyst available for cryopreservation after fresh em-
bryo transfer. The frozen and thawed embryo transfer was
carried out in those patients who failed to conceive after
fresh embryo transfer; 15 patients in Group A and 23 pa-
tients in Group B completed the FET cycles.
Ovarian stimulation, oocyte fertilization, embryo culture
and evaluation
Prior to ovulation induction, all patients underwent
transvaginal ultrasound evaluation with re-measurement
of serum FSH, LH and estradiol on day 3 of the index
cycle. Pituitary down-regulation was realized with GnRH
agonist (GnRH-a, Decapeptyl) on day 21 of the cycle
and followed by recombinant FSH (GONAL-f, Merck
Sereno; Puregon, Organon) for ovarian stimulation as
previously described [6,39,40]. Transvaginal ultrasound
and serum estradiol measurements were periodically
performed to monitor follicular growth and thickness of
endometrial lining. Periovulatory hCG was administered
by subcutaneous injection of recombinant hCG (Ovidrel®,
Merck Serono, Geneva, Switzerland) when at least 3 folli-
cles reached ≥19 mm in diameter. Oocyte retrieval was
conducted by transvaginal ultrasound-guided aspiration
35–36 hours after hCG administration. Oocytes were fer-
tilized with ICSI and fertilization was confirmed with
presence of two pronuclei (PN) and two polar bodies (PB)
16 to 18 hours post ICSI. Embryos were cultured to
blastocyst stage in G1/G2 sequential media (Vitrolife,
Göteborg, Sweden).
In both study groups, blastocysts were evaluated and
scored from 1 to 6 on the basis of degree of blastocyst
expansion and hatching status as described elsewhere
[1,2]. Grade 1 = an early blastocyst with a blastocoele less
than half of the embryo volume; Grade 2 = an intermedi-
ate blastocyst with blastocoele at least half of the embryo
volume; Grade 3 = a full blastocyst with a blastocoele
completely filling the embryo; Grade 4 = an expanded
blastocyst with a blastocoele larger than the full blasto-
cyst and thinning zona pellucida (ZP); Grade 5 = an
hatching blastocyst with herniation of trophectoderm
cells from the ZP; and Grade 6 = an hatched blastocyst
with a blastocyst completely escaped from the ZP. For
blastocysts of grades 3 to 6, the inner cell mass (ICM)
was graded as follows: A =many ICM cells packed
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and C = very few ICM cells. The trophectoderm (TE)
was graded as follows: A =many TE cells forming a co-
hesive epithelium; B = few TE cells forming a loose epi-
thelium and C = very few large TE cells.
Blastocyst biopsy and aCGH testing
In the morphology assessment plus aCGH screening
(Group A), blastocyst biopsy was performed with a
noncontact 1.48 μ diode laser (OCTAX Microscience
GmbH; Bruckberg, Germany) on day 5. Three to five
trophectoderm (TE) cells were aspirated and loaded into
a PCR tube with 2.5 μl 1× PBS as previously described
[6,29,39]. At the same time, assisted hatching (AH) was
performed for all embryos in the morphological assess-
ment alone (Group B). Whole genomic amplification
was performed with the SurePlex DNA amplification kit
(BlueGnome, Cambridge, UK) and aCGH testing was
performed using the 24sure protocol as described previ-
ously [6,39]. In brief, sample and control DNA (8 μl for
each) were labeled with Cy3 and Cy5 fluorophores for
2–4 hours. The labeled DNA was re-suspended in
dexsulphate hybridization buffer and then hybridized on
the 24sure slides overnight. The hybridized slides were
washed in 2× saline sodium citrate (SSC) plus 0.05%
Tween-20 for 10 minutes and then in 1× SSC at room
temperature for 10 minutes. The slides were washed in
0.1× SSC at 60°C for 5 minutes followed by the final
wash in 0.1× SSC at room temperature for 1 minute.
After centrifugation at 200 g for 3 minutes, the 24sure
slides were scanned with a laser scanner at 10 μm
(Agilent Technologies; Santa Clara, USA). BlueFuse
Multi software (BlueGnome, Cambridge, UK) was used
for analysis of microarray data on whole chromosomal
gain and loss across all 24 chromosomes.
Embryo selection for transfer and cryopreservation
In the morphology assessment plus aCGH screening
group, only one euploid blastocyst with the best grade
available was selected for fresh transfer to each patient
and the remaining euploid blastocysts with good morph-
ology (grade 3BB or above) were vitrified on day 6. In
the morphology assessment alone group, a single blasto-
cyst with the best grade available was selected for fresh
transfer based on morphology assessment only and the
remaining blastocysts with good morphology (grade 3BB
or above) were vitrified using the same methods as
Group A.
Blastocyst vitrification and warming
Blastocysts from both Group A and Group B were vitrified
using the Cryotip method as described elsewhere [41]. In
brief, blastocysts were equilibrated in equilibration solu-
tion (ES) containing 7.5% DMSO, 7.5% ethyleneglycol,20% synthetic serum substitute (SSS) or dextran serum
supplement (DSS) for 9 to 12 minutes. They were then
passed through four 20 μl drops of vitrification solution
(VS) containing 15% DMSO, 15% ethyleneglycol, 0.5 M
sucrose and 20% SSS or DSS. After washing in VS drops,
individual blastocysts were loaded into the Cryotips within
90 seconds and plunged into liquid nitrogen immediately.
For warming, the Cryotip was removed from liquid nitro-
gen and thawed in a 37°C water bath for about 3 seconds
and the contents were released as a small drop. The
Cryotip contents were then mixed with the thawing solu-
tion (TS) containing 1.0 M sucrose, 20% SSS or DSS in
Medium-199 for 1 minute. The blastocysts were passed
through two drops of dilution solution (DS) containing
0.5 M sucrose, 20% SSS or DSS. They were then passed
through two drops of washing solution (WS) containing
20% SSS or DSS in Medium-199 before placing into
blastocyst culture medium. After warming, one to two
blastocysts were transferred to each patient depending on
survival of the vitrified blastocysts in individual patients.
No more than two blastocysts were transferred to each
patient.
Patient preparation for FET cycles
In both Group A and Group B, patients were treated using
identical endometrial preparation protocols. In brief, nor-
ethindrone acetate and ethinyl estradiol (Loestrin®24Fe,
Warner Chilcott) were used in combination with estradiol
valerate (Delestrogen, JHP Pharmaceuticals). Preparation
of the endometrium was initiated on day 4 of menstru-
ation with Loestrin®24Fe (1 mg/day) until day 24 of the
cycle. Then a total of six injections of 10 mg Delestrogen
were administered 3 days after onset of menstruation, and
the last injection of Delestrogen was given on the day of
embryo transfer. Endometrial thickness was evaluated by
ultrasound on days 9 to 12. Progesterone (50 mg/day) was
given 3 days before embryo transfer. In cases of preg-
nancy, progesterone was administered for the first 9 weeks
of pregnancy.
Outcome measures and statistical analysis
The percentages of cryopreserved blastocysts and sur-
vival rates after warming were recorded and compared
between Group A and Group B. Pregnancy outcomes
and implantation rates per embryo transferred were also
tabulated and compared between the two study groups.
Differences between groups were assessed by Chi-square
analysis or Fisher’s exact test. A difference of p <0.05
was considered statistically significant.
Results
First time IVF patients with good prognosis were ran-
domized into two study groups: 55 patients in the





























Figure 2 Detail of aCGH results derived from aneuploid
blastocysts (n = 191) in the morphology assessment plus aCGH
screening group. Monosomy = single chromosome loss; Trisomy =
single chromosome gain; Dual = two chromosomal abnormality;
Complex = three or more chromosomal abnormality.
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(Group B). The clinical and demographic features of
the two study groups were similar. For patients in
Group A, a total of 425 blastocysts were biopsied and
analyzed with aCGH. The aCGH analysis revealed that
53.2% (226/425) of the blastocysts were euploid, 44.9%
(191/425) were aneuploid and 1.9% (8/425) had no re-
sults due to DNA amplification failure (Figure 1). The
percentages of each type of chromosomal abnormality
detected in the aneuploid blastocysts were as follows:
35.6% (68/191) single chromosome loss (monosomy),
20.9% (40/191) single chromosome gain (trisomy),
28.8% (55/191) dual chromosomal abnormality and
14.7% (28/191) complex (three or more) chromosomal
abnormality (Figure 2). Of the 191 aneuploid blasto-
cysts, a total of 329 chromosome gains and losses in-
volving all 24 chromosomes were detected by aCGH;
171 losses and 158 gains. While chromosomal abnor-
malities were detected in all chromosomes, disruptions
involving chromosomes 15, 16, 21, 22 and X were ob-
served most frequently. Abnormalities involving chro-
mosomes 4, 5 and 6 were relatively uncommon.
Fresh single embryo transfer was performed on day 6
for all patients and the clinical outcome of the fresh
transfer cycles was reported previously [6]. In summary,
a single euploid blastocyst with the best morphology
grade available was transferred to each patient in the
morphology assessment plus aCGH screening (Group A).
For patients in Group B (without aCGH screening) a
single blastocyst with the best grade available was se-
lected for fresh transfer based on morphology assess-
ment alone (Table 1). The observed clinical pregnancy
rate was significantly higher in Group A compared to
Group B (70.9% vs. 45.8%, respectively; p = 0.017). A
significant increase in ongoing pregnancy rates was also
observed in Group A compared to Group B (69.1% vs.
41.7%, respectively; p = 0.009). There were no signifi-
























Figure 1 A summary of aCGH results derived from biopsied
blastocysts (n = 425) in the morphology assessment plus aCGH
screening group. No results = no results due to DNA
amplification failure.and Group B (2.6% vs. 9.1%, respectively; p >0.05). No
twin pregnancies were identified in either group.
As shown in Table 2, a total of 64 (28.3%) remaining
euploid embryos with good morphology (grade 3 BB or
above) were cryopreserved after fresh embryo transfer in
Group A. For patients in Group B, 389 blastocysts were
microscopically examined and a single blastocyst with
the best grade available was selected for fresh transfer in
each patient. A total of 157 (40.4%) blastocysts with
good morphology (grade 3BB or above) were vitrified in
this group. There was a significant difference in the per-
centage of cryopreserved blastocysts between Group A
and Group B (28.3% vs. 40.4%, respectively; p = 0.003).
Data in Table 3 compare blastocyst survival rates after
warming between the morphology assessment plus
aCGH screening (Group A) and the morphology assess-
ment alone (Group B). In Group A, 15 patients com-
pleted the FET cycles and a total of 22 blastocysts were
thawed; 20 (90.9%) of the blastocysts survived after
warming and were transferred (an average of 1.3 blasto-
cysts per patient). In Group B, 23 patients completed the
FET cycles and a total of 46 blastocysts were thawed. A
total of 42 (91.3%) of the blastocysts survived after
warming and were transferred (an average of 1.8Table 1 Comparison of clinical outcomes of fresh SET
between the morphology assessment plus aCGH
screening (Group A) and the morphology assessment
alone (Group B)
Parameters Group A Group B p value
Patients enrolled 55 48
Patients with fresh SET 55 48
Clinical pregnancy 39 (70.9%) 22 (45.8%) 0.017a
Ongoing pregnancy 38 (69.1%) 20 (41.7%) 0.009a
Miscarriage 1 (2.6%) 2 (9.1%) 0.597b
SET = single embryo transfer, aby Chi-square analysis; bby Fisher’s exact test.
Table 2 A summary of IVF patients’ data for blastocyst
cryopreservation following morphology assessment plus
aCGH screening (Group A), or morphology assessment
alone (Group B)
Parameters Group A Group B
Patients enrolled 55 48
Blastocysts evaluated by morphology 425 389
Blastocysts analyzed by aCGH 425 n/a
Euploid blastocysts identified by aCGH 226 n/a
% Cryopreserved blastocysts among non-
transferred*
28.3% 40.4%
*Group A vs. Group B, p = 0.003 (by Chi-square analysis).
Table 4 Comparison of clinical outcomes of the
subsequent FET cycles between the morphology
assessment plus aCGH screening (Group A) and the
morphology assessment alone (Group B)
Parameters Group A Group B p value
Patients completed FET cycles 15 23
Patients with SET 10 (66.7%) 4 (17.4%)
Patients with DET 5 (33.3%) 19 (82.6%) 0.006a
Clinical pregnancy 10 (66.7%) 12 (52.2%) 0.583a
Ongoing pregnancy
(≥20 weeks GA)
10 (66.7%) 10 (43.5%) 0.286a
Implantation 13 (65.0%) 14 (33.3%) 0.038a
Twin pregnancy 3 (30.0%) 2 (16.7%) 0.624b
Miscarriage 0 2 (16.7%) 0.481b
SET = single embryo transfer, DET = double embryo transer, GA = gestational age;
aby Chi-square analysis; bby Fisher’s exact test.
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significant differences in blastocyst survival rates be-
tween the morphology assessment plus aCGH screening
group and the morphology assessment alone group
(90.9% vs. 91.3%, respectively; p >0.05).
All FET patients were offered transfer of one or two
blastocysts depending on survival of the vitrified blasto-
cysts after warming. Data on frozen and thawed embryo
transfer and pregnancy outcomes are summarized in
Table 4. There was a significantly lower percentage of
patients with double embryo transfer (DET) in the
morphology assessment plus aCGH screening group
compared to the morphology assessment alone group
(33.3% vs. 82.6%, respectively; p = 0.006). There were no
significant differences in clinical pregnancy rates be-
tween Group A and Group B (66.7% vs. 52.2%, respect-
ively; p >0.05). The ongoing pregnancy rate in Group A
was slightly higher than that of Group B (66.7% vs.
43.5%, respectively; p >0.05). However, the implantation
rate per embryo transferred was significantly higher in
the morphology assessment plus aCGH screening group
when compared to the morphology assessment alone
group (65.0% vs. 33.3%, respectively, p = 0.038). More-
over, there was no miscarriage observed in the morph-
ology assessment plus aCGH screening group while a
16.7% miscarriage rate was recorded in the morph-
ology assessment alone group (0% vs. 16.7%, respect-
ively; p >0.05) although the difference was not statistically
significant with the sample size. Additionally, there were
no significant differences in twin pregnancy rates betweenTable 3 Comparison of blastocyst survival after
vitrification and warming between the morphology
assessment plus aCGH screening (Group A) and the
morphology assessment alone (Group B)
Parameters Group A Group B p value
Patients completed FET cycles 15 23
Thawed blastocysts 22 46
Survived blastocysts 20 (90.9%) 42 (91.3%) 0.957*
*by Chi-square analysis; FET = frozen and thawed embryo transfer.Group A and Group B (30.0% vs. 16.7%, respectively;
p >0.05).
Discussion
The advance in embryo cryopreservation technology,
particularly vitrification [41], has led to a substantial in-
crease in cryopreservation of human embryos derived
from IVF cycles [42-44] either for the purpose of redu-
cing the incidence of ovarian hyper-stimulation syn-
drome (OHSS) or for future use in subsequent FET
cycles. Since the first live birth was reported after a
thawed embryo transfer with the traditional freezing
protocols in 1984, frozen-thawed embryo transfer, par-
ticularly with vitrification and warming, has become an
integral part of IVF treatment [45-50]. While embryo
cryopreservation and subsequent FET continue to play
an important role in assisted reproductive procedures
with proven live birth [51-55], it still remains unknown
exactly how new genome-wide molecular testing may
affect the clinical outcome of this aspect of assisted re-
productive treatment [39]. So far, clinical research has
focused on application of such comprehensive chromo-
somal screening technology specifically for patients with
a known translocation, repeated implantation failure or
recurrent pregnancy loss [5,24-28,34], and more recently
for some infertile patients [30,36] as well as first-time
IVF patients with good prognosis [6]. Our previous
reports have demonstrated that aCGH screening for
first-time IVF patients with good prognosis significantly
improves clinical and ongoing pregnancy rates in fresh
embryo transfer cycles [6], while the number of embryos
available for cryopreservation is sharply reduced in the
same group of patients [39]. However, a prospective
study on frozen and thawed embryo transfer as related
to pregnancy and implantation outcomes following
aCGH screening of embryos from IVF patients with
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nosis) has not yet been conducted. While aCGH screen-
ing has been recently applied for selection of euploid
embryo(s) for transfer in fresh and frozen embryo trans-
fer cycles, this is the first prospective investigation into
the impact of aCGH specifically on cryopreservation and
implantation outcomes in subsequent FET cycles of first-
time IVF patients with good prognosis.
Our study contributes new aCGH data on survival of
frozen and thawed blastocysts and pregnancy outcomes
in subsequent FET cycles of young, low-risk IVF pa-
tients. When embryo selection for cryopreservation was
performed on the basis of morphology assessment plus
aCGH screening, 90.9% of the cryopreserved blastocysts
survived after warming. The survival rate of vitrified
blastocysts in the morphology assessment plus aCGH
screening group was similar to that of the morphology
assessment alone group. Moreover, a significantly lower
proportion of blastocysts was available for cryopreserva-
tion in Group A compared to Group B. However, a sig-
nificantly higher implantation rate per embryo transfer
was observed in the morphology assessment plus
aCGH screening group compared to the morphological
assessment alone group (65.0% vs. 33.3%, respectively,
p = 0.038). Furthermore, there was no miscarriage ob-
served in Group A while a 16.7% miscarriage rate was
recorded in Group B (0% vs. 16.7%, respectively, p >0.05).
Our data suggest that selection of euploid blastocysts for
cryopreservation with aCGH screening for IVF patients
may improve the efficiency of FET programs in several
ways: 1) by selecting euploid blastocysts for cryopreserva-
tion to increase implantation rates per embryo transferred
in subsequent FET cycles, 2) by eliminating aneuploidy
blastocysts from the cryopreservation pool to decrease the
risk of miscarriage following frozen and thawed embryo
transfer and 3) by selective cryopreservation of euploid
blastocysts to lower the overall cost associated with cryo-
preservation and storage, especially when such valuable
blastocysts are vitrified and stored individually. A recent
retrospective aCGH study comparing single thawed eu-
ploid embryo to routine age matched IVF patients under-
going blastocyst transfer has yielded similar pregnancy
and implantation outcomes [30].
Our present investigation extends prior observations
on the young and low-risk IVF population and finds
conventional morphological criteria alone to be insuffi-
ciently accurate to select blastocysts for transfer and
cryopreservation [6,39]. Because blastocysts in our con-
trol group (Group B) were selected by morphology as-
sessment alone, they were cryopreserved without any
aneuploidy screening, and therefore have an uncertain
reproductive potential. The observed implantation rate
per embryo transferred was significantly lower in the
morphology assessment group without any aCGHtesting when compared to the morphology assessment
plus aCGH screening group. It has been well docu-
mented that transfer of aneuploid embryos in IVF pa-
tients results in implantation failure, miscarriage or birth
of abnormal babies with serious medical problems
[3,5,14]. The current study provides further evidence of
clinical benefits for IVF patients with aCGH screening
by eliminating the embryos with substantial chromo-
some abnormalities (including monosomy, trisomy, dual
and complex aneuploidy) but with apparently “normal
looking” morphology [3-6,39], which otherwise would
have been destined for transfer and cryopreservation.
Our data suggest that designating an embryo for cryo-
preservation without aCGH comprehensive chromo-
some screening may entail the preservation and storage
of a reproductively incompetent embryo.
Several limitations of our investigation should be
addressed. The frozen and thawed embryo transfer was
carried out only in those patients who failed to conceive
after fresh embryo transfer in both Group A and Group
B since the patients who had become pregnant in the
fresh transfer cycles were not yet ready for the FET cy-
cles. Moreover, considering the negative pregnancy re-
sults in their fresh embryo transfer cycles, patients were
offered to transfer one or two blastocysts depending on
survival of the cryopreserved blastocysts after warming
in individual patients. Some patients had only one
blastocyst available for transfer while the other patients
had more blastocysts available for transfer after
warming. No more than two blastocysts were trans-
ferred to each patient. As a result, there were signifi-
cantly more patients with double embryo transfer in
the Group B than those in Group A (82.6% vs. 33.3%,
respectively, p = 0.006). Additionally, we were not able
to include a power analysis prior to this investigation
because the actual incidence of embryo aneuploidy in
first-time IVF patients with no risk factors is unknown,
and the survival rates of embryos after vitrification and
warming may vary from patient to patient.
Conclusions
The present study demonstrates that aCGH screening of
blastocysts prior to cryopreservation significantly in-
creases implantation rates, and may reduce the risk of
miscarriage in subsequent FET cycles. Our data suggest
that designating an embryo for cryopreservation without
aCGH comprehensive chromosome screening may entail
the preservation and storage of a reproductively incom-
petent embryo. Further randomized clinical studies with
a larger sample size are needed to validate these prelim-
inary findings.
Competing interest
The authors declare that they have no competing interests.
Yang et al. Molecular Cytogenetics 2013, 6:32 Page 7 of 8
http://www.molecularcytogenetics.org/content/6/1/32Authors’ contributions
ZY and JL conceived the research, designed the study, and directed the
aCGH analysis. ZY wrote the manuscript and organized the revisions. XL and
KY were in charge of data mining and statistical analysis. SAS, JL, KY and RDS
were the fertility specialists with oversight of the clinical program. All authors
read and approved the final manuscript.Acknowledgments
The authors thank all the clinical and laboratory staff at Pacific Reproductive
Center, Beijing Jiao En De Yen Hospital and Ninth People’s Hospital, School
of Medicine, Shanghai Jiao Tong University for their assistance with patients’
care and the data collection. We greatly appreciate and deeply thank
Professor Alan Handyside from the London Bridge Fertility, Gynecology and
Genetics Center, London, UK for his comments and correction of the
manuscript.
Author details
1ART and PGD Program, Pacific Reproductive Center, Torrance, CA, USA.
2IVF Division, Beijing Jia En De Yun Hospital, Beijing, People’s Republic of
China. 3Department of Assisted Reproduction, Ninth People’s Hospital,
School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s
Republic of China.
Received: 2 April 2013 Accepted: 30 June 2013
Published: 9 August 2013References
1. Schoolcraft WB, Gardner DK, Lane M, Schlenker T, Hamilton F, Meldrum DR:
Blastocyst culture and transfer: analysis of results and parameters
affecting outcome in two in vitro fertilization programs. Fertl Steril 1999,
72:604–609.
2. Gardner DK, Surrey E, Minjarrez D, Leitz A, Stevens J, Schoolcraft WB: Single
blastocyst transfer: a prospective randomized trial. Fertil Steril 2004,
81:551–555.
3. Fragouli E, Wells D: Aneuploidy screening for embryo selection. Semin
Reprod Med 2012, 30:289–301.
4. Alfarawati S, Fragouli E, Colls P, Stevens J, Gutierrez-Mateo C, Schoolcraft
WB, Wells D: The relationship between blastocyst morphology,
chromosomal abnormality and embryo gender. Fertil Steril 2011,
95:520–524.
5. Hodes-Wertz B, Grifo J, Ghadir S, Kaplan B, Laskin CA, Glassner M, Munné S:
Idiopathic recurrent miscarriage is caused by aneuploid embryos. Fertil
Steril 2012, 98:675–680.
6. Yang Z, Liu J, Collins G, Salem S, Liu X, S-Lyle S, Peck A, Sill ES, Salem R:
Selection of single blastocysts for fresh transfer via stand morphology
assessment alone and with array CGH for good prognosis IVF patients:
results from a randomized pilot study. Mol Cytogenet 2012, 5:24.
7. Hassold T, Hunt P: Maternal age and chromosomally abnormal
pregnancies: what we know and what we knew. Curr Opin Pediatr 2009,
21:703–708.
8. Kuliev A, Cieslak J, Verlinsky Y: Frequency and distribution of chromosome
abnormalities in human oocytes. Cytogenetgenome Res 2005, 111:193–198.
9. Bielanska M, Tan SL, Ao A: Chromosomal mosaicism throughout human
preimplantation development in vitro: incidence, type, and relevance to
embryo outcome. Hum Reprod 2002, 17:413–419.
10. Magli MC, Gianaroli L, Ferraretti AP, Lappi M, Ruberti A, Farfalli V: Embryo
morphology and development are dependent on the chromosomal
complement. Fertil Steril 2007, 87:534–541.
11. Munné S, Sandalinas M, Magli C, Gianaroli L, Cohen J, Warburton D:
Increased rate of aneuploid embryos in young women with previous
aneuploid conceptions. Prenat Diagn 2004, 24:638–643.
12. Munné S, Chen S, Colls P, Garrisi J, Zheng X, Cekleniak N, Lenzi M, Hughes
P, Fischer J, Garrisi M, Tomkin G, Cohen J: Maternal age, morphology,
development and chromosome abnormalities in over 6000 cleavage-
stage embryos. Reprod Biomed Online 2007, 14:628–634.
13. Vanneste E, Voet T, Le Caignec C, Ampe M, Konings P, Melotte C, Debrock
S, Amyere M, Vikkula M, Schuit F, Fryns JP, Verbeke G, D'Hooghe T, Moreau
Y, Vermeesch JR: Chromosome instability is common in human cleavage-
stage embryos. NatMed 2009, 15:577–583.14. Wilton L: Preimplantation genetic diagnosis and chromosome analysis of
blastomeres using comparative genomic hybridization. Hum Reprod
Update 2005, 11:33–41.
15. Staessen C, Platteau P, Van Assche E, Michiels A, Tournaye H, Camus M,
Devroey P, Liebaers I, Van Steirteghem A: Comparison of blastocyst
transfer with or without preimplantation genetic diagnosis for
aneuploidy screening in couples with advanced maternal age: a
prospective randomized controlled trial. Hum Reprod 2004, 19:2849–2858.
16. Hardarson T, Hanson C, Lundin K, Hillensjö T, Nilsson L, Stevic J, Reismer E,
Borg K, Wikland M, Bergh C: Preimplantation genetic screening in women
of advanced maternal age caused a decrease in clinical pregnancy rate:
a randomized controlled trial. Hum Reprod 2008, 23:2806–2812.
17. Schoolcraft WB, Katz-Jaffe MG, Stevens J, Rawlins M, Munné S:
Preimplantation aneuploidy testing for infertile patients of advanced
maternal age: a randomized prospective trial. Fertil Steril 2009,
92:157–162.
18. Masternbroek S, Twisk M, van Echten-Arends J, Sikkema-Raddatz B, Korevaar
JC, Verhoever HR: In vitro fertilization with preimplantation genetic
screening. N Engl JMed 2007, 357:9–17.
19. Masternbroek S, Twisk M, van der Veen F, Repping S: Preimplantation
genetic screening: a systematic review and meta-analysis of RCTs.
Hum Reprod Update 2011, 17:454–466.
20. Voullaire L, Wilton L, Slater H, Williamson R: Detection of aneuploidy in
single cells using comparative genomic hybridization. Prenat Diagn 1999,
19:846–851.
21. Wells D, Delhanty JDA: Comprehensive chromosomal analysis of human
preimplantation embryos using whole genome amplification and single
cell comparative genomic hybridization. Mol Hum Reprod 2000,
6:1055–1062.
22. Sher G, Keskintepe L, Keskintepe M, Ginsburg M, Maassarani G, Yakut T,
Baltaci V, Kotze D, Unsal E: Oocyte karyotyping by comparative genomic
hybridization [correction of hybridization] provides a highly reliable
method for selecting “competent” embryos, markedly improving in vitro
fertilization outcome: a multiphase study. Fertil Steril 2007, 87:1033–1040.
23. Fragouli E, Lenzi M, Ross R, Katz-Jaffe M, Schoolcraft WB, Wells D:
Comprehensive molecular cytogenetic analysis of the human blastocyst
stage embryos. Hum Reprod 2008, 23:2596–2608.
24. Alfarawati S, Fragouli E, Colls P, Wells D: First births after preimplantation
genetic diagnosis of structural chromosome abnormalities using
comparative genomic hybridization and microarray analysis. Hum Reprod
2011, 26:1560–1574.
25. Hellani A, Abu-Amero K, Azouri J, El-Akoum S: Successful pregnancies after
application of array-comparative genomic hybridization in PGS-
aneuploidy screening. Reprod Biomed Online 2008, 17:814–817.
26. Fishel S, Gordon A, Lynch C, Ndukwe G, Kelada E, Thomton S, Jenner L,
Cater E, Brown A, Garcia-Bernardo J: Live birth after polar body array
comprehensive genomic hybridization prediction of embryo ploidy –
the future of IVF. Fertil Steril 2010, 93:1006.e7–1006.e10.
27. Gutierrez-Mateo C, Colls P, Sanchez-Garcia J, Escudero T, Prates R, Ketterson
K, Wells D, Munné S: Validation of microarray comparative genomic
hybridization for comprehensive chromosome analysis of embryos. Fertil
Steril 2011, 95:953–958.
28. Fioretino F, Spizzichino L, Bono S, Birricik A, Kokkali G, Rienzi L, Ubaldi FM,
Lammarrone E, Gordon A, Pantos K: PGD for reciprocal and Robertsonian
translocation using array comparative genomic hybridization. Hum
Reprod 2011, 26:1925–1935.
29. Yang Z, Salem S, Salem-Lyle S, Bayrak A, Salem RD: Trophectoderm cells
derived from blastocyst biopsy are suitable for array CGH analysis of
24 chromosomes. Fertil Steril 2011, 95(Suppl 4):S23. Abstr.
30. Grifo JA, Hodes-Wertz B, Lee H-L, Amperloquio E, Clark-Williams M, Adler A:
Single thawed euploid embryo transfer improves IVF pregnancy,
miscarriage, and multiple gestation outcomes and has similar
implantation rates as egg donation. J Assist Reprod Genet 2013,
30:259–264.
31. Treff NR, Su J, Tao X, Levy B, Scott RT: Accurate single cell 24 chromosome
aneuploidy screening using whole genome amplification and single
nucleotide polymorphism microarrays. Fertil Steril 2010, 94:2017–2021.
32. Northrop LE, Treff NR, Levy B, Scott R Jr: SNP microarray-based 24
chromosome aneuploidy screening demonstrates that cleavage-stage
FISH poorly predicts aneuploidy in embryos that develop to
morphologically normal blastocysts. Mol Hum Reprod 2010, 16:590–600.
Yang et al. Molecular Cytogenetics 2013, 6:32 Page 8 of 8
http://www.molecularcytogenetics.org/content/6/1/3233. Johnson DS, Gemelos G, Baner J, Ryan A, Cinnioglu C, Banjevic M, Ross R,
Alper M, Barrett B, Frederick J, Potter D, Behr B, Rabinowitz M: Preclinical
validation of a microarray method for full molecular karyotyping of
blastomeres in a 24-h protocol. Hum Reprod 2010, 25:1066–1075.
34. Schoolcraft WB, Treff NR, Stevens JM, Ferry K, Katz-Jaffe M, Scott R Jr: Live
birth outcome with trophectoderm biopsy, blastocyst vitrification, and
single-nucleotide polymorphism microarray-based comprehensive
chromosome screening in infertile patients. Fert Steril 2011, 96:638–640.
35. Handyside AH: PGD and aneuploidy screening for 24 chromosome by
genome-wide SNP analysis: seeing the woods and the trees. Reprod
Biomed Online 2011, 23:686–691.
36. Forman EJ, Tao X, Ferry KM, Taylor D, Treff NR, Scott R Jr: Single embryo
transfer with comprehensive chromosome screening results in improved
ongoing pregnancy rates and decreased miscarriage rates. Hum Reprod
2012, 27:1217–1222.
37. Sills ES, Yang Z, Walsh D, Salem S: Comprehensive genetic assessment of
the human embryo: can empiric application of microarray comparative
genomic hybridization reduce multiple gestation rate by single fresh
blastocyst transfer? Archgynecol Obstet 2012, 286:755–761.
38. Harper JC, Sengupta SB: Preimplantation genetic diagnosis: State of the
ART 2011. Humgenet 2012, 131:175–186.
39. Liu J, Sills ES, Yang Z, Salem S, Rahil T, Collins G, Liu X, Salem R: Array
comparative genomic hybridization screening in IVF significantly
reduces number of embryos available for cryopreservation. Clin Exp
ReprodMed 2012, 39:52–57.
40. Sills ES, Schattman GL, Veeck LL, Liu HC, Prasad M, Rosenwaks Z:
Characteristics of consecutive in vitro fertilization cycles among patients
treated with follicle-stimulating hormone (FSH) and human menopausal
gonadotropin versus FSH alone. Fertil Steril 1998, 69:831–835.
41. Kuwayama M, Vajta G, Iada S, Kato O: Comparison of open and closed
methods for vitrification of human embryos and the elimination of
potential contamination. Reprod Biomed Online 2005, 11:608–614.
42. deMouzon J, Goossens V, Bhattacharya S, Castilla JA, Ferraretti AP, Korsak V,
Kupka M, Nygren KG, Andersen AN: Assisted reproductive technology in
Europe, 2006: results generated from European registers by ESHRE.
Hum Reprod 2010, 25:1851–1862.
43. deMouzon J, Goossens V, Bhattacharya S, Castilla JA, Ferraretti AP, Korsak V,
Kupka M, Nygren KG, Nyboe Andersen A: Assisted reproductive
technology in Europe, 2007: results generated from European registers
by ESHRE. Hum Reprod 2012, 27:954–966.
44. Ferraretti AP, Goossens V, deMouzon J, Bhattacharya S, Castilla JA, Korsak V,
Kupka M, Nygren KG, Nyboe Andersen A: Assisted reproductive
technology in Europe, 2008: results generated from European registers
by ESHRE. Hum Reprod 2012, 27:2571–2584.
45. Maheshwari A, Pandey S, Shetty A, Hamilton M, Bhattacharya S: Obstetric
and perinatal outcomes in singleton pregnancies resulting from the
transfer of frozen thawed versus fresh embryos generated through
in vitro fertilization treatment: a systematic review and meta-analysis.
Fertil Steril 2012, 98:368–377.
46. Cobo A, Diaz C: Clinic application of oocyte vitrification: a systematic
review and meta-analysis of randomized controlled trials. Fertil Steril
2011, 96:277–285.
47. Rezazadeh VM, Eftekhari-Yazdi P, Karimian L: Vitrification versus slow
freezing gives excellent survival, post warming embryo morphology and
pregnancy outcomes for human cleaved embryos. Assist Reprod Genet
2009, 26:347–354.
48. Chang EM, Han JE, Kim YS, Lyu SW, Lee WS, Yoon TK: Use of the natural
cycle and vitrification thawed blastocyst transfer results in better in-vitro
fertilization outcomes: cycle regimens of vitrification thawed blastocyst
transfer. J Assist Reprod Genet 2011, 28:369–374.
49. Zhu D, Zhang J, Cao S, Zhang J, Heng BC, Huang M, Ling X, Duan T, Tong
GQ: Vitrified-warmed blastocyst transfer cycles yield higher pregnancy
and implantation rates compared with fresh blastocyst transfer cycles–
time for a new embryo transfer strategy? Fertil Steril 2011, 95:1691–1695.
50. Kansal Kalra S, Ratcliffe SJ, Milman L, Gracia CR, Coutifaris C, Barnhart K:
Perinatal morbidity after in vitro fertilization is lower with frozen embryo
transfer. Fertil Steril 2011, 95:548–553.
51. Wada I, Macnamee MC, Wick K, Bradfield JM, Brinsden PR: Birth
characteristics and perinatal outcome of babies conceived from
cryopreserved embryos. Hum Reprod 1994, 9:543–546.52. Wikland M, Hardarson T, Hillensjo T, Westin C, Westlander G, Wood M,
Wennerholm UB: Obstetric outcomes after transfer of vitrified blastocysts.
Hum Reprod 2010, 25:1699–1707.
53. Aflatoonian A, MansooriMoghaddam F, Mashayekhy M, Mohamadian F:
Comparison of early pregnancy and neonatal outcomes after frozen and
fresh embryo transfer in ART cycles. J Assist Reprod Genet 2010,
27:695–700.
54. Wang YA, Sulliban EA, Black D, Dean J, Bryant J, Chapman M: Preterm birth
and low birth weight after assisted reproductive technology-related
pregnancy in Australia between 1996 and 2000. Fertil Steril 2005,
83:1650–1658.
55. Wennerholm UB, SoderstromAnttila V, Bergh C, Aittomaki K, Hazekamp J,
Nygren KG, Selbing A, Loft A: Children born after cryopreservation of
embryos of oocytes: a systematic review of outcome data. Hum Reprod
2009, 24:2158–2172.
doi:10.1186/1755-8166-6-32
Cite this article as: Yang et al.: Selection of euploid blastocysts for
cryopreservation with array comparative genomic hybridization (aCGH)
results in increased implantation rates in subsequent frozen and
thawed embryo transfer cycles. Molecular Cytogenetics 2013 6:32.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
